3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

NCT05265052 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer Pain

Interventions

DRUG: 3D1002 (50 mg)(Phase IIa)
DRUG: 3D1002 (100 mg)(Phase IIa)
DRUG: 3D1002 (150 mg)(Phase IIa)
DRUG: 3D1002 monotherapy (Phase IIb)
DRUG: OxyContin monotherapy (Phase IIb)
DRUG: 3D1002 + OxyContin (Phase IIb)

Sponsor

3D Medicines